Last $18.61 USD
Change Today +0.11 / 0.59%
Volume 162.4K
VIVO On Other Exchanges
As of 5:20 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

meridian bioscience inc (VIVO) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/10/14 - $27.72
52 Week Low
09/16/14 - $18.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

meridian bioscience inc (VIVO) Related Bloomberg News

View More Bloomberg News

meridian bioscience inc (VIVO) Related Businessweek News

No Related Businessweek News Found

meridian bioscience inc (VIVO) Details

Meridian Bioscience Inc., an integrated life science company, manufactures, develops, sells, and distributes diagnostic test kits. These are used primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. It also makes and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. In addition, it contract-manufactures proteins and other biologicals for biopharmaceutical and biotechnology companies researching new drugs and vaccines. Its products and technologies are marketed to hospitals, reference labs, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in about 60 countries. Meridian, founded in 1976, is based in Cincinnati.

550 Employees
Last Reported Date: 11/29/13
Founded in 1976

meridian bioscience inc (VIVO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $901.4K
Founder and Executive Chairman
Total Annual Compensation: $901.4K
Chief Financial Officer, Principal Financial ...
Total Annual Compensation: $393.7K
Executive Vice President of Operations and In...
Total Annual Compensation: $408.9K
President of Meridian Bioscience Europe and M...
Total Annual Compensation: $529.6K
Compensation as of Fiscal Year 2013.

meridian bioscience inc (VIVO) Key Developments

Meridian Bioscience, Inc., Board Meeting, Sep 15, 2014

Meridian Bioscience, Inc., Board Meeting, Sep 15, 2014. Agenda: To elect John A. Kraeutler as its Chairman.

Meridian Bioscience, Inc. Signs Agreement with Premier, Inc. to Offer the Complete Illumigene(R) Molecular Menu of Tests to its Members

Meridian Bioscience, Inc. announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene(R) molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations. The illumigene molecular system utilizes loop-mediated isothermal DNA amplification (LAMP) technology, an efficient system which allows Meridian to provide customers the illumipro--10(TM) instrument without a capital investment or costly annual service contract. The illumigene procedure is simple, highly sensitive, and yields results in less than one hour, which helps drive improvements in the early diagnosis and treatment of preventable diseases.

Meridian Bioscience, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2015; Re-Affirms Earnings Guidance for the Year 2014

Meridian Bioscience, Inc. announced that based on the company's business planning and budgeting activities for the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 to $200 million, or 2% to 5% growth, and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.2 million at fiscal 2014 year end to 42.4 million at fiscal 2015 year end. The revenues and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2015. Management reaffirms fiscal 2014 guidance of per share diluted earnings of between $0.85 - $0.90 on net sales of $190 million to $195 million, with current revenue and earnings expectations being near the low end of the range.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIVO:US $18.61 USD +0.11

VIVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ERBA Diagnostics Inc $3.56 USD -0.19
Luminex Corp $19.36 USD +0.45
Nanosphere Inc $0.60 USD -0.01
Neogen Corp $40.39 USD -0.30
OraSure Technologies Inc $7.38 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation VIVO Industry Range
Price/Earnings 21.8x
Price/Sales 4.0x
Price/Book 4.8x
Price/Cash Flow 21.5x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERIDIAN BIOSCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at